FDA red and green lights: January 2025
AstraZeneca bags three of the month’s four oncology approvals.
A Leap into the subgroups
On a wing and a prayer Leap heads for phase 3.
ASCO-GI – a second colorectal win for Bristol's combo
Opdivo and Yervoy succeed again, but the US path remains unclear.
ASCO-GI – Exelixis’s son of Cabometyx disappoints
The company might need something better to replace its ageing blockbuster.
ASCO-GI – no masking Xilio's setback
Poor efficacy clouds prospects for the company's "improved" Yervoy.
Vir shows up Sanofi
Two masked bispecific antibodies, licensed for $100m, produce promising early data.
